Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04804007 · ClinicalTrials.gov registry record · Phase 2

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

A Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, sponsored by Nabil Adra.

Recruiting
Registry status
Phase 2
Development phase
64
Enrollment target
1
Study location

NCT04804007: Recruiting Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, sponsored by Nabil Adra.

NCT04804007 is a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor that is actively recruiting participants, run by Nabil Adra. The registered enrollment target is 64 participants, below the 344-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04804007, a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, is actively recruiting participants, sponsored by Nabil Adra.

RECRUITING
Registry status
Phase 2
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).

Primary Outcome

Investigator determination of tumor progression (clinical, radiographic, tumor markers including AFP and hCG)

Interventions

  • DRUG Etoposide

Study Locations (1)

Indiana

  • Indiana University Melvin & Bren Simon Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2021-03-03
Est. Completion 2028-12
Phase Phase 2
Nabil Adra

4 total trials

What NCT04804007 shows while recruiting

NCT04804007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 344-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (81% lower).

The record links to 3 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Etoposide is the first listed.

NCT04804007 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT04804007 about?

NCT04804007 is a clinical study titled "Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT". This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).

What is the current status of trial NCT04804007?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2021-03-03. Estimated completion is 2028-12.

What conditions does trial NCT04804007 study?

This clinical trial studies the following conditions: Germ Cell Tumor, Ovarian Germ Cell Tumor, Non-seminomatous Germ Cell Tumor.

What interventions are being tested in trial NCT04804007?

The interventions under investigation include: Etoposide (DRUG).

Who is sponsoring clinical trial NCT04804007?

This trial is sponsored by Nabil Adra, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04804007 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Germ Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04804007's enrollment target sits among peer trials

64 10th of 19 higher than 10 of 19 other Germ Cell Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04804007, the US trial registry maintained by the National Library of Medicine. NCT04804007 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.